Horizon Therapeutics (HZNP) Misses Q1 EPS by 13c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Horizon Therapeutics (HZNP) Tepezza is Now Underway, Add Stock - Cowen
May 5, 2021 11:30 AM EDTCowen analyst Ken Cacciatore reiterated an Outperform rating and $120.00 price target on Horizon Therapeutics (NASDAQ: HZNP) following Q1 results with the resupply of Tepezza is now underway.
The analyst commented, "We have never encountered a product that launched and within three... More
